Skye, Redx Reverse-Merge Into Fibrx, a $125M Fibrosis Play

Skye Bioscience (Nasdaq: SKYE) is reverse-merging with U.K.-based Redx Pharma to form Fibrx Therapeutics, a fibrosis-focused company backed by $125 million in fresh financing. The combined company keeps Skye’s Nasdaq listing but operates under the Fibrx name with Redx’s management team and board in charge. The deal, structured as a U.K. scheme of arrangement, is expected to close in Q4 2026. The cycle’s later deals include the Lisata-Marea reverse merger, which paired a microcap shell with a cardioendocrine pipeline.

It is the second fibrosis reverse merger of the 2026 biotech cycle, following Werewolf’s reverse merger with Ambros earlier in August. The pattern is survival, not a premium buyout. Skye paused its anti-obesity program nimacimab and sought strategic alternatives in the second quarter, leaving a cash-constrained public shell. Redx, whose own 2023 reverse merger collapsed when Concentra Biosciences swooped in and bought Jounce instead, finally gets a Nasdaq listing and runway into 2029.

The $125 million arrives in three tranches: a $68 million PIPE from Abingworth, British Business Bank, NEXTBio Capital, 5AM Ventures, and Redmile; a $36 million Redx Series A led by Abingworth; and a $22 million equity line from Redmile. When the dust settles, pre-transaction Skye holders own 5.38% of the company, Redx investors 46.17%, and the new financing syndicate 48.45%. Skye shareholders also get a contingent value right to 90% of any proceeds from monetizing nimacimab.

The asset that justifies the deal is RXC008, a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn’s disease, the scarring form of IBD. Approved anti-inflammatory drugs such as anti-TNFs, anti-IL-23s, and JAK inhibitors quiet inflammation but do not reverse established strictures. RXC008 targets the ROCK pathway, the signaling cascade that drives the fibrotic remodeling behind those strictures, and in preclinical studies it reversed fibrosis in the gut. It holds FDA Fast Track designation and an open U.S. IND, with a Phase 2 study starting in the second half of 2026 and topline data expected in H2 2028.

Fibrx also carries a preclinical DDR inhibitor and RXC007 (zelasudil), a ROCK2 inhibitor that finished a Phase 2 signal search in idiopathic pulmonary fibrosis and is available for partnering. Redx CEO Lisa Anson, a 20-year AstraZeneca veteran, will lead the combined company.

Skye shares closed at $2.17 Monday after a 1-for-8 reverse split that took effect August 24. Fibrx is expected to carry roughly 934 million fully diluted shares.

Source: Skye Bioscience – Redx Pharma transaction press release

What to watch: the Phase 2 fibrostenotic Crohn’s readout in H2 2028 is the whole thesis. If RXC008 shows it can reverse gut fibrosis, the ROCK pathway becomes a new IBD battleground. Until then, Fibrx is a reverse-merger survival bet on a long clinical clock.

What It Means for the Trade

Read the cap table before the science. Pre-transaction Skye holders own 5.38% of Fibrx, Redx investors 46.17%, and the new money 48.45% — this is a Redx IPO through a Skye shell, and the $2.17 share price (post 1-for-8 reverse split) mostly reflects that the public stub is small. Skye holders’ real consolation is the contingent value right to 90% of nimacimab monetization proceeds, which is a call option on an asset the market had already stopped underwriting. The $125 million in tranches ($68 million PIPE, $36 million Series A, $22 million equity line) funds runway into 2029 — through the Phase 2 readout, which is the only event that matters.

The pattern is the 2026 cycle’s signature: a paused or failed pipeline company hands its listing to a venture-backed private with a real asset. Werewolf-Ambros did it, Fulcrum-Slate did it, and the Lisata-Marea deal is the cardioendocrine version of the same trade. None of these is a premium exit. This is survival structuring, and the honest framing is that Fibrx is a pre-Phase-2 biotech with a two-year wait to data, wrapped in a fresh Nasdaq ticker.

Mechanism and Market Context

RXC008’s thesis addresses a genuine gap in IBD. Anti-TNFs, anti-IL-23s, and JAK inhibitors suppress inflammation, but fibrostenotic Crohn’s — the scarring that narrows and obstructs the bowel — is mechanical damage those drugs do not reverse. The ROCK pathway drives the fibrotic remodeling behind strictures, and RXC008 is GI-restricted, meaning it acts locally where delivered rather than systemically, which is the safety argument for chronic dosing in a pathway (ROCK) with cardiovascular effects when inhibited body-wide. FDA Fast Track and an open US IND de-risk the regulatory entry; the preclinical gut-fibrosis reversal data is the biological hook.

The competitive whitespace is real: stricture management today is endoscopic dilation or surgery, and the pharmacologic options are absent. A drug that reverses established fibrosis would create its own category in Crohn’s, with read-through to other fibrotic diseases if the ROCK thesis translates. Zelasudil’s completed IPF Phase 2 signal search and the preclinical DDR program give the company a second act to shop to partners.

Risks and What Could Go Wrong

1. The 2028 clock. Topline in H2 2028 means years of burn before evidence; the $125 million is sized to arrive, not to survive a surprise.
2. Translation risk. Preclinical fibrosis reversal has disappointed in humans many times across many mechanisms; the ROCK case in gut specifically is unproven in patients.
3. Reverse-merger drift. Small floats with heavy insider ownership trade on sentiment until the Phase 2 approaches; expect long flat stretches.
4. Concentration. RXC008 is the thesis; zelasudil is a partnering option, not a pipeline.

A disciplined speculator’s ticket: cheap relative to runway, honest about being a single-asset wait. Size it to forget about it until 2028.